Form 4 for AVTX Avalo Therapeutics, Inc.
Accepted 2025-12-12 00:00:00 ET · period of report 2025-12-10 · accession 0001470831-25-000409 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-12 | 2025-12-10 | AVTX | Sullivan Christopher Ryan | CFO | F - Tax | $4.10 | -155 | 17.3K | -0.9% | -$635.50 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-10 | F | D | 155 | $4.10 | 17,338 | D | — | — | (F1) Includes 417 additional shares acquired pursuant to the Issuer's Employee Stock Purchase Plan as a part of this reporting transaction. |